Science 37

Science 37 is not a traditional CRO; it is a centralized clinical trial site. It operates under a single Form FDA 1572 and a single central IRB, and deploys 150+ employed, research-grade nurses to patients' homes. This model removes the need for sponsors to activate and manage dozens of independent brick-and-mortar sites.

The company states it has undergone five Phase 3 trial inspections that resulted in No Action Indicated (NAI) classifications with zero Form 483 observations. It is, per its own description, the first and only direct-to-patient site to be inspected by the FDA.

A peer-reviewed analysis with the Tufts Center for the Study of Drug Development found that Science 37 contributes approximately 20–30% of total enrollment as a single site, with an 86% study completion rate. Specific trials in narcolepsy, vascular Ehlers-Danlos syndrome, and colorectal cancer prevention exceeded industry enrollment-rate norms by significant margins.

Science 37 actively recruits across at least 14 therapeutic areas, including cardiovascular, CNS, oncology, infectious disease, pediatrics, dermatology, respiratory, and women's health. The firm has supported over 200 trials from Phase I through Phase IV and observational studies.

It is headquartered in Morrisville, North Carolina, and operates with medical licensure in all 50 US states. The firm does not disclose additional international offices or trial sites on its website.